References
- Holmdng S, Hedelin H, Anderström C, Holmberg E, Johansson SL. The importance of the depth of invasion in stage Ti bladder carcinoma: a prospective cohort study. J Urol 1997;157:800 —4.
- Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003;43:241–5.
- Brauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer; is cystectomy often too early? J Urol 2001;165:808–10.
- Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumours. J Urol 1999;162: 74–6.
- Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of Ti bladder cancer. Urology 2002;60:822–5.
- Grimm M-O, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vögeli TA. Effect of repeat transurethral resection for superficial bladder cancer; a long term observa-tional study. J Urol 2003;170:433–7.
- Kaasinen E, Wijkstrom H, MalmströmHellsten S,Duchek M, Mestad 0, et al. The members of the Nordic Urothelial Cancer Group. Alternating Mitomycin C and BCG instillations versus BCG alone in treatment of carci-noma in situ of the urinary bladder: A Nordic Study. Eur Urol 2003;43: 637–45.
- Griffiths TRL, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002;167:2408–12.
- Shahin O, Thalmann GN, Rentsch C, Mazzuchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage Ti grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003;169: 96–100.
- Böhle A, Jocham D, Bock PB. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90–5.
- Sylvester RJ, van den Meijden APM, Lamm DL. Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964–70.
- Duna SC, Smith Jr JA, Shapell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk non-muscle invasive urothelial carcinoma treated with radical cystect-omy. J Urol 2001;166:490–3.
- Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296–9.
- Raitanen MP, Lukkarinen 0. A controlled study of intrave-sical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carci-noma of the bladder. Br J Urol 1995;76: 697–701.